Spyre Therapeutics Inc (SYRE)

Guggenheim reiterated $SYRE Buy-$65-Top Pick & said 'DUET readout remains a key focus for investors, and we think that $JNJ could disclose the data at UEG 2025 [#UEGWEEK] (although we could be waking up to a press release imminently).' $JNJ $RHHBY $MRK Guggenheim said in its research report: Last week, we hosted a series of investor meetings with $SYRE's CEO (Cameron Turtle), CFO (Scott Burrows), and VP of Finance & IR (Eric Mclntyre). Key takeaways include:

$SYRE just got a nice divy

$SYRE - Spyre Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors SYRE’s 2025 10-Q risk factors reveal heightened regulatory, IP, and commercialization challenges, expanded focus on third-party reliance, internal control weaknesses, intensified macroeconomic and geopolitical risks, and increased capital needs amid evolving FDA and market uncertainties. #Biotechnology #CapitalNeeds #MacroeconomicRisk #IntellectualProperty #RegulatoryRisk 🟢 Added 🟠 Removed https://d-risk.ai/SYRE/10-Q/2025-08-05

$SYRE "Heads up alert! Upcoming earnings on Thursday, 8/7/2025 for $SYRE Neutral (5.2) ### Financial Analysis: Spyre Therapeutics, Inc. (NASDAQ: SYRE) operates as a clinical-stage biotechnology company focused on innovative treatments for immune-mediated diseases, specifically inflammatory bowel disease (IBD). The company has strategically positioned itself within the biotechnology sector, which is known for its high growth potential but also its inherent risks due to the significant R&D investments required. Key financial metrics indicate that Spyre is in a developmental phase with no significant revenue streams yet. The company's price-to-earnings (P/E) ratio is not applicable as it is not currently generating profits. However, the focus on cash burn is crucial, as biotechnology firms often operate at a loss during early stages. Recent analysis suggests that Spyre is managing its cash burn effectively, maintaining sufficient runway to continue its clinical trials and development activities. Spyre's EPS growth is not currently measurable due to its pre-revenue status, but analysts are optimistic about its pipeline of therapies targeting IBD, which could lead to substantial revenue growth upon successful commercialization. Revenue forecasts remain speculative but are expected to commence post-approval of its lead candidates. Compared to its industry peers, Spyre is in a competitive position regarding its technological advancements in antibody engineering and therapeutic optimization. Its strategic approach to therapy development could potentially yield a competitive edge in efficacy and patient convenience, critical factors in its market segment. ### Upcoming Earnings Report: Spyre's upcoming earnings report is anticipated with moderate interest from the market, primarily focusing on updates regarding its clinical trials and financial health rather than revenue figures. Historically, the company has maintained transparency in its communication, which has fostered investor confidence despite the lack of immediate profitability. Analysts consensus estimates do not foresee significant changes in earnings but will pay close attention to any announcements regarding strategic partnerships, pipeline progress, and funding initiatives. The impact on the stock is likely to be more sentiment-driven, hinging on the management's guidance and clarity regarding future milestones. ### Sector Performance: The biotechnology sector, to which Spyre belongs, has experienced mixed performance recently. While innovation and breakthroughs continue to drive interest and investment, the sector faces volatility due to regulatory challenges and market conditions such as interest rates and investor risk appetite. Companies with robust pipelines and clear paths to commercialization, like Spyre, are positioned to weather these challenges better, but they remain subject to broader sector trends. - Funds were net buyers of $SYRE during the previous reporting quarter. - Funds with large holdings in $SYRE include: - Perceptive Advisors LLC, MV: $37MM. Fund Rank: 61% www.perceptivelife.com - Paradigm Biocap, MV: $34MM. Fund Rank: 55% - Adage Capital P, MV: $13MM. Fund Rank: 86% www.adagecapital.com - Deerfield Management Co, MV: $7MM. Fund Rank: 90% www.deerfield.com - Armistice Capital LLC, MV: $3MM. Fund Rank: 72% www.armisticecapital.com - Last 10 days performance: 3% - Last 30 days performance: 9% - Last 90 days performance: 12% Some of the latest news articles: - Title: Spyre Therapeutics Announces Grants of Inducement Awards Publication Date: 8/1/2025 8:41:00 PM, Source: yahoo URL: https://finance.yahoo.com/news/spyre-therapeutics-announces-grants-inducement-204100494.html?.tsrc=rss - Title: Here's Why We're Not Too Worried About Spyre Therapeutics' (NASDAQ:SYRE) Cash Burn Situation Publication Date: 7/15/2025 12:25:27 PM, Source: yahoo URL: https://finance.yahoo.com/news/heres-why-were-not-too-122527282.html?.tsrc=rss - Title: Spyre Therapeutics Announces Grants of Inducement Awards Publication Date: 7/3/2025 8:05:00 PM, Source: yahoo URL: https://finance.yahoo.com/news/spyre-therapeutics-announces-grants-inducement-200500096.html?.tsrc=rss Follow us on stocktwits.com and Substack (chessgmstocks.substack.com). Not a financial advice. Not a trading signal."

$ARWR $VRDN $ORKA $SYRE Pika's dumpster diving was quite successful 🤿

$SYRE just reverted 5% higher to -13% (~514Kv) a few minutes ago, 06/20 options, follow for more volatility.

$SYRE they obviously have a lot of immunogenicity in their phase 1 study which is why they’re not disclosing the incidence, and so the HUGE question is what happens when they give a second dose? Of course there is no impact of immunogenicity when a single dose is given to treatment naive subjects, but dosing subjects with pre-existing ADA (from the first dose) could be a very different situation.

$SYRE Spyre Therapeutics reports positive interim Phase 1 results for TL1A antibodies Spyre Therapeutics announced positive interim Phase 1 results from its first-in-human trials of SPY002 and SPY072, two investigational, novel, extended half-life monoclonal antibodies targeting TL1A. In addition, the company is initiating its SKYLINE-UC platform trial and unveiled its SKYWAY-RD basket trial evaluating anti-TL1A targeted therapy in three rheumatologic indications. Interim results from the Phase 1 trials for SPY002 and SPY072, with data reported as of May 30, 2025, met all Phase 1 objectives, supporting their potential to become next-generation anti-TL1A monotherapies in immune-mediated diseases or as elements of combination therapies. Single doses of up to 1500 mg for SPY002 and SPY072 were well tolerated with no serious adverse events reported, exhibited a prolonged half-life supportive of quarterly or less frequent dosing, and suppressed free TL1A through 20 weeks of follow up available for the lowest dose tested. Building on these Phase 1 results, Spyre is advancing SPY002 into the SKYLINE-UC platform trial - initiated in May 2025 - for ulcerative colitis. SKYLINE-UC is expected to include SPY001, SPY002, SPY003, and combinations thereof under an efficient single master protocol. The SKYWAY-RD study is a Phase 2 basket trial investigating Spyre's improved anti-TL1A as a treatment for RA, PsA, and axSpA and is expected to initiate in Q3 2025. In 2026 the company expects to readout open-label monotherapy data for its three investigational long-acting antibodies from the SKYLINE-UC trial along with three placebo-controlled readouts for SPY072 in RA, PsA, and axSpA from the SKYWAY-RD trial. In 2027, the company expects to read out placebo-controlled data of its monotherapies and combination therapies from the SKYLINE-UC study.

$SYRE Spyre Therapeutics Announces Interim Phase 1 Results For Two Next-Generation TL1A Antibody Programs, And Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts

$SYRE Spyre Therapeutics, watch for a narrow range breakout at https://stockconsultant.com/?SYRE